Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Immuneering Corporation
- Enrolment target
- 510
- Started
- 5 June 2026
- Main results due
- June 2028
- Study sites
- 51
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment naive as follows: * First-line PDAC participants will have received no previous systemic anti-cancer therapy * Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria * Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values Exclusion Criteria: * Inability to swallow oral medications * Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma * Participants with only locally advanced disease * Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Study sites(51)
Clearview Cancer Institute
Huntsville, Alabama, United States
Recruiting
City of Hope
Phoenix, Arizona, United States
Recruiting
City of Hope
Duarte, California, United States
Recruiting
University of California San Diego
San Diego, California, United States
Recruiting
Poudre Valley Health Care, Inc
Fort Collins, Colorado, United States
Recruiting
Rocky Mountain Cancer Centers
Lone Tree, Colorado, United States
Recruiting
Medical Oncology Hematology Consultants
Newark, Delaware, United States
Recruiting
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Recruiting
Florida Cancer Specialists - South
Sarasota, Florida, United States
Recruiting
Florida Cancer Specialists - North
St. Petersburg, Florida, United States
Recruiting
Florida Cancer Specialists - East
West Palm Beach, Florida, United States
Recruiting
Piedmont Cancer Institute
Atlanta, Georgia, United States
Recruiting
Piedmont Healthcare
Atlanta, Georgia, United States
Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois, United States
Recruiting
City of Hope
Chicago, Illinois, United States
Recruiting
OSF Medical Center
Peoria, Illinois, United States
Recruiting
University of Kansas Cancer Center
Fairway, Kansas, United States
Recruiting
Maryland Oncology
Columbia, Maryland, United States
Recruiting
Missouri Cancer Associates
Columbia, Missouri, United States
Recruiting
Comprehensive Cancer Centers
Las Vegas, Nevada, United States
Recruiting
Regional Cancer Care
Belleville, New Jersey, United States
Recruiting
NYU Langone Health
New York, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
FirstHealth of the Carolinas
Pinehurst, North Carolina, United States
Recruiting
Taylor Cancer Research Center
Maumee, Ohio, United States
Recruiting
Willamette Valley Cancer Institute
Eugene, Oregon, United States
Recruiting
Oregon Health and Science University
Portland, Oregon, United States
Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Recruiting
Avera Cancer Institute Research
Sioux Falls, South Dakota, United States
Recruiting
West Cancer Center
Germantown, Tennessee, United States
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Recruiting
Texas Oncology - West Texas
Abilene, Texas, United States
Recruiting
Texas Oncology - Austin
Austin, Texas, United States
Recruiting
Texas Oncology - San Antonio
San Antonio, Texas, United States
Recruiting
Texas Oncology Gulf Coast
Webster, Texas, United States
Recruiting
Blue Ridge Cancer Care
Blacksburg, Virginia, United States
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Recruiting
University of Washington Fred Hutchinson Cancer Center
Seattle, Washington, United States
Recruiting
Northwest Cancer Specialists
Vancouver, Washington, United States
Recruiting
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Recruiting
Nepean Cancer Care Centre
Kingswood, New South Wales, Australia
Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Recruiting
Genesiscare
Waratah, New South Wales, Australia
Recruiting
Icon Cancer Centre - Chermside
Chermside, Queensland, Australia
Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Recruiting
Cancer Research South Australia
Adelaide, South Australia, Australia
Recruiting
Bayside Health
Frankston East, Victoria, Australia
Recruiting
Caucasus Medical Centre
Tbilisi, TB, Georgia
Recruiting
LTD "Multiprofile Clinic Consilium Medulla"
Tbilisi, TB, Georgia
Recruiting
Imperial College Healthcare NHS
London, LND, United Kingdom
Recruiting
Showing 51 of 51 sites. 51 of the 51 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07562152. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me